L3VLUP
ProSign in

TEVA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TEVALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TEVA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTEVALLY
Q3 20207 holders, $2.1bn33 holders, $14.1bn
Q4 20205 holders, $2.2bn29 holders, $17.3bn
Q1 20218 holders, $2.6bn24 holders, $23.0bn
Q2 20217 holders, $2.1bn24 holders, $27.8bn
Q3 20216 holders, $1.7bn31 holders, $29.9bn
Q4 20214 holders, $1.1bn31 holders, $34.7bn
Q1 20229 holders, $1.4bn24 holders, $35.3bn
Q2 202211 holders, $913m33 holders, $42.7bn
Q3 202211 holders, $1.4bn31 holders, $43.4bn
Q4 202211 holders, $1.7bn31 holders, $46.6bn
Q1 20238 holders, $1.3bn33 holders, $44.3bn
Q2 202310 holders, $184m37 holders, $59.6bn
Q3 202313 holders, $384m44 holders, $67.6bn
Q4 202310 holders, $373m45 holders, $73.6bn
Q1 202416 holders, $666m41 holders, $95.3bn
Q2 202422 holders, $1.8bn43 holders, $110bn
Q3 202422 holders, $2.3bn45 holders, $107bn
Q4 202418 holders, $3.0bn46 holders, $93.9bn
Q1 202512 holders, $2.0bn42 holders, $98.4bn
Q2 202511 holders, $1.8bn43 holders, $93.2bn
Q3 202514 holders, $964m39 holders, $86.7bn
Q4 202516 holders, $2.1bn41 holders, $123bn
Q1 202614 holders, $2.0bn39 holders, $106bn
Q2 202614 holders, $2.4bn44 holders, $132bn
TEVA

Teva Pharmaceutical Inds LTD

Holders
16
Reported value
$2.1bn
Buyers
18
Sellers
22

Breadth -4 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TEVA (5)

ARK Investment Management LLC, Farallon Capital Management LLC, Glenview Capital Management LLC, Greenlight Capital, Verition Fund Management LLC

Only LLY (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, Soros Fund Management LLC, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →